Nice catch EnriqueSuave. Thanks for sharing.
Theralase is not on the list of that meeting but we can track when these meetings are being held in the future.
All those mentioned in your link have indeed published are news release:
Example:
March 8 -
Roche - Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer But remember the goofy Bunge with his famous pathetic "
Hurry up boys!" thinking that Keytruda was a threat (while it was the complete opposite)while looking, I found this that shows Keytruda is failing in lung cancer.
By chance, TLT didn't cut corners just to satisfy Bungee's insatiable need for a share price just for a share price as opposed to a clear focus on clinical results and what it takes to bring us much further in terms of valuation thanks to a dominance as the next reference in NMIBC, NSCLC, GBM.
Merck withdraws Keytruda for lung cancer amid FDA crackdown (clinicaltrialsarena.com) Continued approval for this indication was contingent upon completion of the post-marketing requirement establishing superiority of KEYTRUDA as determined by overall survival (OS). As announced in Jan. 2020, KEYNOTE-604, the confirmatory Phase 3 trial for this indication, met one of its dual primary endpoints of progression-free survival but did not reach statistical significance for the other primary endpoint of OS.
Merck’s consultation with the FDA on this withdrawal is part of an industry-wide evaluation of indications based on accelerated approvals that have not yet met their post-marketing requirements.